The FreeStyle Libre 3 app serves as the digital interface for Abbott Laboratories' latest continuous glucose monitoring system, representing the company's most advanced offering in the competitive CGM market. This iOS application pairs exclusively with FreeStyle Libre 3 sensors to provide diabetes patients with comprehensive glucose tracking capabilities, positioning itself as a medical-grade monitoring solution rather than a general wellness tool. Core functionality centers on real-time glucose data transmission, with readings updated every 60 seconds—significantly faster than previous generations and competing systems. The application delivers customizable high and low glucose alerts, though these remain optional features that users must manually enable. Detailed reporting functions allow for trend analysis over 8-hour, 24-hour, and 90-day periods, providing both immediate feedback and long-term metabolic pattern recognition. All data syncs automatically to Abbott's cloud platform, enabling remote sharing with healthcare providers through the LibreView web portal. User experience reflects a clinical design philosophy with straightforward navigation and data presentation. The interface prioritizes clarity over aesthetic appeal, displaying current glucose values in large numerals with color-coded trend arrows indicating direction and rate of change. Real-world usage patterns show most users check the app 10-15 times daily, with meal logging and insulin dose tracking requiring manual input. The absence of Apple Watch compatibility remains a significant operational constraint, forcing users to retrieve their iPhone for every glucose check despite the system's continuous monitoring capabilities. User feedback consistently highlights both appreciation for recent performance improvements and frustration regarding missing features. Multiple five-star reviews from July-August 2025 acknowledge enhanced graph loading speeds (Smitty13234, August 3) and general reliability (Ghillcastillo, July 30), while simultaneously requesting Apple Watch integration (MAMT1171, August 19) and retrospective event logging (Basetzer, July 27). The 2.35/5 aggregate rating suggests these limitations significantly impact user satisfaction despite the app's core functionality meeting medical requirements. The application demonstrates clear strengths in medical accuracy and data frequency but suffers from integration limitations common in regulated healthcare applications. It serves best as part of a comprehensive diabetes management system for patients committed to frequent iPhone access, while proving less suitable for users seeking seamless wearable integration or retrospective data modification capabilities. The disconnect between clinical effectiveness and user convenience expectations explains the moderate rating despite technical competence.